Clinical Trial Update: Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo [Phase 2, Phase 3]

View source ↗

Summary

Completed vehicle-controlled efficacy and safety study (Phase 2/3) evaluating two dose regimens of CD07223 1.5% topical gel in impetigo.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impetigo

Drugs mentioned

• CD07223 1.5% Topical Gel (CD07223)

Snippet

Sponsor: NovaBay Pharmaceuticals, Inc. | Conditions: Impetigo | Phase 2, Phase 3 | Status: COMPLETED